Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis

Ewa Bryl, Abbe N. Vallejo, Eric Lawrence Matteson, Jacek M. Witkowski, Cornelia M. Weyand, Jorg J. Goronzy

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Objective. The immune system of patients with rheumatoid arthritis (RA) is characterized by the accumulation of CD4+ T cells deficient in CD28 expression and the up-regulation of tumor necrosis factor α (TNFα). Previous in vitro studies have shown that TNFα induces transcriptional silencing of the CD28 gene. Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFα. Methods. Patients with RA and age-matched individuals were recruited. Peripheral blood mononuclear cells were stained for CD3, CD4, CD8, CD28, TNF receptor I (TNFRI), and TNFRII, and analyzed by quantitative flow cytometry. The number of CD28 and TNFR molecules was monitored in a subgroup of patients with RA undergoing treatment with anti-TNFα. Results. In addition to higher frequencies of CD28null T cells, patients with RA had significantly reduced numbers of CD28 and TNFRI molecules on CD4+,CD28+ T cells. Normal expression could be restored in vitro by overnight culture, suggesting that CD28 in patients was modulated by exogenous factors. In contrast, treatment with TNFα in vitro resulted in further down-regulation. CD28 expression was normalized in patients undergoing TNFα-neutralizing therapy. Conclusion. Overproduction of TNFα in RA induces a global down-regulation of CD28 in CD4+ T cells and may cause reduced sensitivity to costimulatory signals in T cell responses.

Original languageEnglish (US)
Pages (from-to)2996-3003
Number of pages8
JournalArthritis and Rheumatism
Volume52
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
T-Lymphocytes
Tumor Necrosis Factor Receptors
Therapeutics
Down-Regulation
Immunocompetence
CD4 Antigens
Gene Silencing
Immune System
Blood Cells
Flow Cytometry
Up-Regulation
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis. / Bryl, Ewa; Vallejo, Abbe N.; Matteson, Eric Lawrence; Witkowski, Jacek M.; Weyand, Cornelia M.; Goronzy, Jorg J.

In: Arthritis and Rheumatism, Vol. 52, No. 10, 10.2005, p. 2996-3003.

Research output: Contribution to journalArticle

Bryl, Ewa ; Vallejo, Abbe N. ; Matteson, Eric Lawrence ; Witkowski, Jacek M. ; Weyand, Cornelia M. ; Goronzy, Jorg J. / Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 10. pp. 2996-3003.
@article{39970d84d3bb4e22bee723aba46c4ae6,
title = "Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis",
abstract = "Objective. The immune system of patients with rheumatoid arthritis (RA) is characterized by the accumulation of CD4+ T cells deficient in CD28 expression and the up-regulation of tumor necrosis factor α (TNFα). Previous in vitro studies have shown that TNFα induces transcriptional silencing of the CD28 gene. Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFα. Methods. Patients with RA and age-matched individuals were recruited. Peripheral blood mononuclear cells were stained for CD3, CD4, CD8, CD28, TNF receptor I (TNFRI), and TNFRII, and analyzed by quantitative flow cytometry. The number of CD28 and TNFR molecules was monitored in a subgroup of patients with RA undergoing treatment with anti-TNFα. Results. In addition to higher frequencies of CD28null T cells, patients with RA had significantly reduced numbers of CD28 and TNFRI molecules on CD4+,CD28+ T cells. Normal expression could be restored in vitro by overnight culture, suggesting that CD28 in patients was modulated by exogenous factors. In contrast, treatment with TNFα in vitro resulted in further down-regulation. CD28 expression was normalized in patients undergoing TNFα-neutralizing therapy. Conclusion. Overproduction of TNFα in RA induces a global down-regulation of CD28 in CD4+ T cells and may cause reduced sensitivity to costimulatory signals in T cell responses.",
author = "Ewa Bryl and Vallejo, {Abbe N.} and Matteson, {Eric Lawrence} and Witkowski, {Jacek M.} and Weyand, {Cornelia M.} and Goronzy, {Jorg J.}",
year = "2005",
month = "10",
doi = "10.1002/art.21353",
language = "English (US)",
volume = "52",
pages = "2996--3003",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis

AU - Bryl, Ewa

AU - Vallejo, Abbe N.

AU - Matteson, Eric Lawrence

AU - Witkowski, Jacek M.

AU - Weyand, Cornelia M.

AU - Goronzy, Jorg J.

PY - 2005/10

Y1 - 2005/10

N2 - Objective. The immune system of patients with rheumatoid arthritis (RA) is characterized by the accumulation of CD4+ T cells deficient in CD28 expression and the up-regulation of tumor necrosis factor α (TNFα). Previous in vitro studies have shown that TNFα induces transcriptional silencing of the CD28 gene. Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFα. Methods. Patients with RA and age-matched individuals were recruited. Peripheral blood mononuclear cells were stained for CD3, CD4, CD8, CD28, TNF receptor I (TNFRI), and TNFRII, and analyzed by quantitative flow cytometry. The number of CD28 and TNFR molecules was monitored in a subgroup of patients with RA undergoing treatment with anti-TNFα. Results. In addition to higher frequencies of CD28null T cells, patients with RA had significantly reduced numbers of CD28 and TNFRI molecules on CD4+,CD28+ T cells. Normal expression could be restored in vitro by overnight culture, suggesting that CD28 in patients was modulated by exogenous factors. In contrast, treatment with TNFα in vitro resulted in further down-regulation. CD28 expression was normalized in patients undergoing TNFα-neutralizing therapy. Conclusion. Overproduction of TNFα in RA induces a global down-regulation of CD28 in CD4+ T cells and may cause reduced sensitivity to costimulatory signals in T cell responses.

AB - Objective. The immune system of patients with rheumatoid arthritis (RA) is characterized by the accumulation of CD4+ T cells deficient in CD28 expression and the up-regulation of tumor necrosis factor α (TNFα). Previous in vitro studies have shown that TNFα induces transcriptional silencing of the CD28 gene. Because reduced expression of CD28 in T cells compromises immunocompetence, we examined whether CD28 expression is reduced in patients with RA in vivo and whether the reduction is related to TNFα. Methods. Patients with RA and age-matched individuals were recruited. Peripheral blood mononuclear cells were stained for CD3, CD4, CD8, CD28, TNF receptor I (TNFRI), and TNFRII, and analyzed by quantitative flow cytometry. The number of CD28 and TNFR molecules was monitored in a subgroup of patients with RA undergoing treatment with anti-TNFα. Results. In addition to higher frequencies of CD28null T cells, patients with RA had significantly reduced numbers of CD28 and TNFRI molecules on CD4+,CD28+ T cells. Normal expression could be restored in vitro by overnight culture, suggesting that CD28 in patients was modulated by exogenous factors. In contrast, treatment with TNFα in vitro resulted in further down-regulation. CD28 expression was normalized in patients undergoing TNFα-neutralizing therapy. Conclusion. Overproduction of TNFα in RA induces a global down-regulation of CD28 in CD4+ T cells and may cause reduced sensitivity to costimulatory signals in T cell responses.

UR - http://www.scopus.com/inward/record.url?scp=26844513278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844513278&partnerID=8YFLogxK

U2 - 10.1002/art.21353

DO - 10.1002/art.21353

M3 - Article

C2 - 16200579

AN - SCOPUS:26844513278

VL - 52

SP - 2996

EP - 3003

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -